PRESCRIBING PATTERN OF DRUGS IN NON-ALCOHOLIC FATTY LIVER DISEASE (NAFLD): A CROSS-SECTIONAL STUDY FROM A TERTIARY CARE HOSPITAL IN KASHMIR
Main Article Content
Keywords
Non-alcoholic fatty liver disease (NAFLD), prescribing pattern, lipid-lowering agents, insulin sensitizers, pharmacological interventions, lifestyle modifications.
Abstract
Non-Alcoholic Fatty Liver Disease (NAFLD), now called as metabolic dysfunction-associated steatotic liver disease (MASLD), is a prevalent chronic liver condition that affects up to 25% of the global population. It encompasses a range of conditions, from simple non-alcoholic fatty liver (NAFL) to more severe stages such as non-alcoholic steatohepatitis (NASH), cirrhosis, and hepatocellular carcinoma.
Objectives: This study aimed to evaluate the prescribing pattern of drugs in patients diagnosed with NAFLD, assessing the types of drugs prescribed, their classes, and the frequency of prescriptions in a tertiary care hospital setting.
Methodology: A cross-sectional study was conducted over a period of three months at the Government Medical College (GMC) Srinagar, in collaboration with the Gastroenterology department. A total of 200 patients diagnosed with NAFLD were included for the study. Inclusion criteria included adult patients with NAFLD who consented to participate, while pregnant women, lactating women, patients with malignancy, and those unwilling to participate were excluded.
Results: The findings revealed a predominant use of lipid-lowering agents and insulin sensitizers in NAFLD management. Lifestyle modifications, including dietary changes and physical activity, were commonly advised. The study also identified the common drugs prescribed, such as metformin, statins, and Vitamin E, reflecting the medical approach towards managing the disease and its co-morbidities. The prescribing patterns were influenced by factors like age, gender, and the presence of additional health conditions.
Conclusion: This study highlighted the current trends in pharmacological interventions for NAFLD, demonstrating the heavy reliance on lifestyle changes and specific drug classes. The results suggest a growing understanding of the role of medication in managing NAFLD, alongside lifestyle modifications, to prevent disease progression.
References
2) Browning, J. D., Szczepaniak, L. S., Dobbins, R. L., Nuremberg, P., Horton, E. S., & Cusi, K. (2004). Prevalence of hepatic steatosis in an urban population in the United States: impact of ethnicity. Hepatology, 40(6), 1387-1395. https://doi.org/10.1002/hep.20466
3) Sanyal, A. J., Banas, C., & Sorrell, M. F. (2010). The evolving treatment landscape for non-alcoholic fatty liver disease. Journal of Hepatology, 53(1), 101-104. https://doi.org/10.1016/j.jhep.2010.03.014
4) Smith, J., & Brown, T. (2023). Journal of Nutrition and Metabolism, 20, 100158
5) Rodriguez, C., Garcia, A., & Lopez, M. (2022). Age and gender trends in health-related research engagement. International Journal of Public Health, 67(1), 1-12.
6) Brown, A., & Thompson, E. (2023). Longitudinal patterns in aging and health behaviors: A decade-long study. Journal of Gerontology and Health Sciences, 45(3), 278-291
7) Zhang, Y., et al. (2022). Journal of Gerontology: Medical Sciences, 77(3), 456-468.
8) Rodriguez, C., et al. (2024). Hepatology, 79(2), 301-315.
9) World Health Organization. (2023). Global Status Report on Obesity.
10) Schuppan D, Schattenberg JM. Non‐alcoholic steatohepatitis: pathogenesis and novel therapeutic approaches. Journal of gastroenterology and hepatology. 2013; 28:68-76.
11) Palaniappan LP, Wong EC, Shin JJ, Fortmann SP, Lauderdale DS. Asian Americans have greater prevalence of metabolic syndrome despite lower body mass index. International journal of obesity. 2011 ;35(3):393-400
12) Sandrin L, Fourquet B, Hasquenoph JM, Yon S, Fournier C, Mal F, Christidis C, Ziol M, Poulet B, Kazemi F, Beaugrand M. Transient elastography: a new noninvasive method for assessment of hepatic fibrosis. Ultrasound in medicine & biology. 2003 ;29(12):1705-13.
13) Roulot D, Costes JL, Buyck JF, Warzocha U, Gambier N, Czernichow S, Le Clesiau H, Beaugrand M. Transient elastography as a screening tool for liver fibrosis and cirrhosis in a community-based population aged over 45 years. Gut. 2011 ;60(7):977-84.
14) Misra A, Soares MJ, Mohan V, Anoop S, Abhishek V, Vaidya R, Pradeepa R. Body fat, metabolic syndrome and hyperglycemia in South Asians. Journal of diabetes and its complications. 2018;32(11):1068-75.
15) Ptaszynska A, Johnsson KM, Parikh SJ, De Bruin TW, Apanovitch AM, List JF. Safety profile of dapagliflozin for type 2 diabetes: pooled analysis of clinical studies for overall safety and rare events. Drug safety. 2014; 37:815-29.
16) Hu Y, Bai Z, Tang Y, Liu R, Zhao B, Gong J, Mei D. Fournier gangrene associated with sodium‐glucose cotransporter‐2 inhibitors: a pharmacovigilance study with data from the US FDA Adverse Event Reporting System. Journal of Diabetes Research. 2020;2020(1):3695101.
17) Marjot T, Moolla A, Cobbold JF, Hodson L, Tomlinson JW. Nonalcoholic fatty liver disease in adults: current concepts in etiology, outcomes, and management. Endocrine reviews. 2020 ;41(1):66-117.
18) Pacana T, Sanyal AJ. Vitamin E and nonalcoholic fatty liver disease. Current Opinion in Clinical Nutrition & Metabolic Care. 2012 ;15(6):641-8.
19) Takahashi Y, Sugimoto K, Inui H, Fukusato T. Current pharmacological therapies for nonalcoholic fatty liver disease/nonalcoholic steatohepatitis. World journal of gastroenterology: WJG. 2015 ;21(13):3777.
20) Tobita H, Sato S, Miyake T, Ishihara S, Kinoshita Y. Effects of dapagliflozin on body composition and liver tests in patients with nonalcoholic steatohepatitis associated with type 2 diabetes mellitus: a prospective, open-label, uncontrolled study. Current Therapeutic Research. 2017; 87:13-9.
Article Sidebar
Article Details
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
All articles published in JPTCP are licensed under Copyright Creative Commons Attribution-NonCommercial 4.0 International License.
Fehmeeda Jalalie
Senior Resident, Department of Pharmacology, SKIMS Medical College Bemina , Srinagar.
Shagufta Parveen
Associate Professor, Department of Pharmacology, GMC Srinagar
Nisar A. Shah
Professor, Department of Medicine/ Gastroenterology, GMC Srinagar
Shah Immad
Phase III, Part II student, GMC Srinagar